por
Lynn Shapiro, Writer | January 06, 2009
Johnson & Johnson said it has completed its tender offer for shares of Omrix Biopharmaceuticals Inc., a New York-based maker of sealants used to control bleeding during surgery.
The $438 million acquisition, initially announced November 24, 2008, is meant to broaden J&J's Ethicon surgical products division. Before buying Omrix, J&J had been a backer of Omrix's technologies, including its experimental fibrin-based products being explored for tissue engineering and repair as well as soft tissue fixation, according to UBS investment analyst, Erik Schneider, who had given the company a "buy" rating.
J&J said Omrix shareholders tendered about 97.8 percent of shares in response to the J&J offer that expired on midnight, January 2, 2009. Remaining shares will be converted into the right to receive $25 in cash for each Omrix share.

Ad Statistics
Times Displayed: 38392
Times Visited: 1042 Stay up to date with the latest training to fix, troubleshoot, and maintain your critical care devices. GE HealthCare offers multiple training formats to empower teams and expand knowledge, saving you time and money
Boards of both companies have approved the deal, as has the Israeli government. Omrix's manufacturing facilities are located in Tel Aviv.